{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:45:12Z","timestamp":1770291912280,"version":"3.49.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":2331,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.4103\/0255-0857.148369","type":"journal-article","created":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T10:11:48Z","timestamp":1420193508000},"page":"3-15","source":"Crossref","is-referenced-by-count":43,"title":["Dengue vaccines: Challenges, development, current status and prospects"],"prefix":"10.1016","volume":"33","author":[{"given":"A","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4103\/0255-0857.148369_bib1","unstructured":"World Health Organization, Geneva, 2013. Dengue and severe dengue [factsheet no. 117, revised September 2013]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs117\/en\/ [Last accessed on 2013 Dec 5]."},{"key":"10.4103\/0255-0857.148369_bib2","unstructured":"Centers for Disease Control and Prevention, Atlanta. Dengue. Available from: http:\/\/www.cdc.gov\/dengue\/ [Last accessed on 2013 Dec 5]."},{"key":"10.4103\/0255-0857.148369_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev.micro.62.081307.163005","article-title":"Global spread and persistence of dengue","volume":"62","author":"Kyle","year":"2008","journal-title":"Annu Rev Microbiol"},{"key":"10.4103\/0255-0857.148369_bib4","doi-asserted-by":"crossref","first-page":"7221","DOI":"10.1016\/j.vaccine.2011.07.022","article-title":"The pathogenesis of dengue","volume":"29","author":"Whitehorn","year":"2011","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib5","unstructured":"World Health Organization, Geneva, 2009. Dengue: Guidelines for diagnosis, treatment, prevention and control. Available from: http:\/\/whqlibdoc.who.int\/publications\/2009\/9789241547871_eng.pdf [Last accessed on 2013 Dec 5]."},{"key":"10.4103\/0255-0857.148369_bib6","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.vaccine.2009.12.035","article-title":"Denguev2V\u2013new global initiative supporting transition from vaccine to vaccination","volume":"28","author":"Lam","year":"2010","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4269\/ajtmh.2011.10-0503","article-title":"Economic impact of dengue illness in the Americas","volume":"84","author":"Shepard","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(07)61687-0","article-title":"Dengue","volume":"370","author":"Halstead","year":"2007","journal-title":"Lancet"},{"key":"10.4103\/0255-0857.148369_bib9","unstructured":"World Health Organization, Geneva, 2012. Global Strategy for dengue prevention and control, 2012\u20132020: WHO report. Available from: http:\/\/www.who.int\/denguecontrol\/9789241504034\/en\/ [Last accessed on 2013 Dec 10]."},{"key":"10.4103\/0255-0857.148369_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0966-842X(01)02288-0","article-title":"Epidemic dengue\/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century","volume":"10","author":"Gubler","year":"2002","journal-title":"Trends Microbiol"},{"key":"10.4103\/0255-0857.148369_bib11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib12","first-page":"311","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered","volume":"42","author":"Halstead","year":"1970","journal-title":"Yale J Biol Med"},{"key":"10.4103\/0255-0857.148369_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.chom.2008.08.004","article-title":"Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: Implications for vaccine development","volume":"4","author":"Pierson","year":"2008","journal-title":"Cell Host Microbe"},{"key":"10.4103\/0255-0857.148369_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-1656(99)00037-1","article-title":"A recombinant Fab neutralizes dengue virus in vitro","volume":"69","author":"Thullier","year":"1999","journal-title":"J Biotechnol"},{"key":"10.4103\/0255-0857.148369_bib15","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00018-010-0357-z","article-title":"Dengue virus life cycle: Viral and host factors modulating infectivity","volume":"67","author":"Rodenhuis-Zybert","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.4103\/0255-0857.148369_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.chom.2010.01.004","article-title":"Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease","volume":"7","author":"Zellweger","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.4103\/0255-0857.148369_bib17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/(SICI)1096-9071(200004)60:4<432::AID-JMV11>3.0.CO;2-7","article-title":"Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996\u20131997 dengue-2 outbreak in French Polynesia","volume":"60","author":"Murgue","year":"2000","journal-title":"J Med Virol"},{"key":"10.4103\/0255-0857.148369_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev-immunol-031210-101315","article-title":"Immune response to dengue virus and prospects for a vaccine","volume":"29","author":"Murphy","year":"2011","journal-title":"Ann Rev Immunol"},{"key":"10.4103\/0255-0857.148369_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/infdis\/jiq060","article-title":"The necessity and quandaries of dengue vaccine development","volume":"203","author":"Thomas","year":"2011","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4161\/hv.5.1.6348","article-title":"Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults","volume":"5","author":"Sun","year":"2009","journal-title":"Hum Vaccine"},{"key":"10.4103\/0255-0857.148369_bib21","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.vaccine.2005.09.029","article-title":"Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults","volume":"24","author":"Kitchener","year":"2006","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib22","first-page":"369","article-title":"Dengue vaccine\u2013current progress and challenges","volume":"98","author":"Swaminathan","year":"2010","journal-title":"Curr Sci"},{"key":"10.4103\/0255-0857.148369_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4269\/ajtmh.2002.66.264","article-title":"Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: Role of serotype concentration, ratio, and multiple doses","volume":"66","author":"Sabchareon","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib24","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/S0264-410X(01)00020-2","article-title":"Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers","volume":"19","author":"Kanesa-thasan","year":"2001","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1006\/viro.1999.9887","article-title":"Development of a novel mouse model for dengue virus infection","volume":"263","author":"An","year":"1999","journal-title":"Virology"},{"key":"10.4103\/0255-0857.148369_bib27","doi-asserted-by":"crossref","first-page":"9729","DOI":"10.1128\/JVI.72.12.9729-9737.1998","article-title":"Study of Dengue virus infection in SCID mice engrafted with human K562 cells","volume":"72","author":"Lin","year":"1998","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib28","doi-asserted-by":"crossref","first-page":"11634","DOI":"10.1128\/JVI.00996-07","article-title":"A het- erologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques","volume":"81","author":"Chen","year":"2007","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1006\/viro.2002.1462","article-title":"Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment and antibody responses against wild- type dengue virus isolates","volume":"298","author":"Guirakhoo","year":"2002","journal-title":"Virology"},{"key":"10.4103\/0255-0857.148369_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0042-6822(03)00542-7","article-title":"Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys","volume":"315","author":"Raviprakash","year":"2003","journal-title":"Virology"},{"key":"10.4103\/0255-0857.148369_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4236\/wjv.2011.14012","article-title":"Dengue vaccines: Challenge and confrontation","volume":"1","author":"Perng","year":"2011","journal-title":"World J Vaccin"},{"key":"10.4103\/0255-0857.148369_bib32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/QCO.0b013e32834a1b0b","article-title":"Critical issues in dengue vaccine development","volume":"24","author":"Thomas","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4269\/ajtmh.1952.1.30","article-title":"Research on dengue during World War II","volume":"1","author":"Sabin","year":"1952","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1086\/382280","article-title":"Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand","volume":"189","author":"Endy","year":"2004","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib35","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1086\/503372","article-title":"Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination","volume":"193","author":"Sun","year":"2006","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib36","doi-asserted-by":"crossref","first-page":"e1536","DOI":"10.1371\/journal.pntd.0001536","article-title":"Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using Fc\u03b3R-expressing cells","volume":"6","author":"Moi","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.4103\/0255-0857.148369_bib37","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3851\/IMP1288","article-title":"Dengue vaccine development and dengue viral neutralization and enhancement assays","volume":"14","author":"Jin","year":"2009","journal-title":"Antivir Ther"},{"key":"10.4103\/0255-0857.148369_bib38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4269\/ajtmh.2009.08-0625","article-title":"Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance","volume":"81","author":"Thomas","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib39","unstructured":"World Health Organization, Geneva, 2008. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Available from: http:\/\/whqlibdoc.who.int\/hq\/2008\/WHO_IVB_08.12_eng.pdf [Last accessed on 2013 Dec 12]."},{"key":"10.4103\/0255-0857.148369_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrmicro1690","article-title":"Prospects for a dengue virus vaccine","volume":"5","author":"Whitehead","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.4103\/0255-0857.148369_bib41","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4161\/hv.5.8.9008","article-title":"Advances in dengue vaccine development","volume":"8","author":"Raviprakash","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.4103\/0255-0857.148369_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.4103\/0255-0857.148369_bib43","series-title":"Vaccines","first-page":"1042","article-title":"Dengue vaccines","author":"Halstead","year":"2013"},{"key":"10.4103\/0255-0857.148369_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0264-410X(00)00040-2","article-title":"Live attenuated tetravalent dengue vaccine","volume":"18S","author":"Bhamarapravati","year":"2000","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib45","first-page":"189","article-title":"Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers","volume":"65","author":"Bhamarapravati","year":"1987","journal-title":"Bull World Health Organ"},{"key":"10.4103\/0255-0857.148369_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0264-410X(95)00167-Y","article-title":"Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers","volume":"14","author":"Vaughn","year":"1996","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib47","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(89)92471-9","article-title":"Study of bivalent dengue vaccine in volunteers","volume":"1","author":"Bhamarapravati","year":"1989","journal-title":"Lancet"},{"key":"10.4103\/0255-0857.148369_bib48","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1016\/j.vaccine.2006.03.066","article-title":"Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3)","volume":"24","author":"Sanchez","year":"2006","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jiq022","article-title":"Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains","volume":"203","author":"Balas","year":"2011","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.2003.69.6_suppl.0690024","article-title":"Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates","volume":"69","author":"Sun","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 6","key":"10.4103\/0255-0857.148369_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4269\/ajtmh.2003.69.17","article-title":"Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines: Selection of safe and immunogenic monovalent vaccines","volume":"69","author":"Kanesa-Thasan","year":"2003","journal-title":"Am J Trop Med Hyg"},{"issue":"Suppl 6","key":"10.4103\/0255-0857.148369_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2003.69.48","article-title":"Phase 1 trial of 16 formulations of a tetravalent live-attenuated dengue vaccine","volume":"69","author":"Edelman","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4269\/ajtmh.2008.78.426","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children","volume":"78","author":"Simasathien","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4269\/ajtmh.2011.10-0501","article-title":"Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants","volume":"85","author":"Watanaveeradej","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4269\/ajtmh.2012.12-0361","article-title":"A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults","volume":"88","author":"Thomas","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib56","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1099\/0022-1317-78-9-2287","article-title":"Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells","volume":"78","author":"Puri","year":"1997","journal-title":"J Gen Virol"},{"key":"10.4103\/0255-0857.148369_bib57","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/JVI.77.2.1653-1657.2003","article-title":"A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3\u2032 untranslated region is highly attenuated and immunogenic in monkeys","volume":"77","author":"Whitehead","year":"2003","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib58","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1128\/JVI.70.6.3930-3937.1996","article-title":"Dengue type 4 virus mutants containing deletions in the 3\u2032 noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys","volume":"70","author":"Men","year":"1996","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.2001.65.405","article-title":"Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3\u2032-untranslated region","volume":"65","author":"Durbin","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib60","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4269\/ajtmh.2001.65.414","article-title":"A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes","volume":"65","author":"Troyer","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib61","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/S0264-410X(03)00488-2","article-title":"Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys","volume":"21","author":"Whitehead","year":"2003","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib62","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/JVI.73.4.3095-3101.1999","article-title":"Yellow fever\/Japanese encephalitis chimeric viruses: Construction and biological properties","volume":"73","author":"Chambers","year":"1999","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib63","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1073\/pnas.88.22.10342","article-title":"Construction of intertypic chimeric dengue viruses by substitution of structural protein genes","volume":"88","author":"Bray","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4103\/0255-0857.148369_bib64","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1128\/JVI.74.12.5477-5485.2000","article-title":"Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates","volume":"74","author":"Guirakhoo","year":"2000","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib65","first-page":"6","article-title":"Development of Sanofi Pasteur tetravalent dengue vaccine","author":"Guy","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.4103\/0255-0857.148369_bib66","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib67","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib68","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4269\/ajtmh.2009.80.302","article-title":"Evaluation of interferences between dengue vaccine 33. serotypes in a monkey model","volume":"80","author":"Guy","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib69","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","article-title":"Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.4103\/0255-0857.148369_bib70","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib71","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1016\/j.vaccine.2011.03.057","article-title":"Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines","volume":"29","author":"Capeding","year":"2011","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib72","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/649916","article-title":"A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults","volume":"201","author":"Morrison","year":"2010","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib73","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0140-6736(12)61428-7","article-title":"Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial","volume":"38","author":"Sabchareon","year":"2012","journal-title":"Lancet"},{"key":"10.4103\/0255-0857.148369_bib74","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1371\/journal.pntd.0000757","article-title":"Emergence of the Asian 1 genotype of dengue virus serotype 2 in Vietnam: In vivo fitness advantage and lineage replacement in south-east Asia","volume":"4","author":"Vu","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.4103\/0255-0857.148369_bib75","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3201\/eid1908.121864","article-title":"Call to action for dengue vaccine failure","volume":"19","author":"Mahalingam","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib76","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/INF.0b013e31829b8022","article-title":"Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: A randomized, controlled, phase II trial in Latin America","volume":"32","author":"Villar","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.4103\/0255-0857.148369_bib77","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1016\/j.vaccine.2011.07.020","article-title":"Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever","volume":"29","author":"Osorio","year":"2011","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib78","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1128\/JVI.77.21.11436-11447.2003","article-title":"Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development","volume":"7","author":"Huang","year":"2003","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib79","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4269\/ajtmh.2011.10-0592","article-title":"Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in cynomolgus macaques","volume":"84","author":"Osorio","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib80","unstructured":"World Health Organization, Geneva, 2013. Dengue vaccine candidates in clinical development. Available from: http:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/april\/1_Dengue_SAGE_Apr2013_Vaccine_Candidates.pdf [Last accessed on 2013 Dec 10]."},{"key":"10.4103\/0255-0857.148369_bib81","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4269\/ajtmh.2004.71.811","article-title":"Genetically modified, live attenuated dengue virus type 3 vaccine candidates","volume":"71","author":"Blaney","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib82","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.vaccine.2007.11.082","article-title":"Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3\u2032 untranslated region (3\u2032-UTR) or by exchange of the DENV-3 3\u2032-UTR with that of DENV-4","volume":"26","author":"Blaney","year":"2008","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib83","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.1016\/j.vaccine.2011.07.023","article-title":"Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine","volume":"29","author":"Durbin","year":"2011","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib84","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jis936","article-title":"A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial","volume":"207","author":"Durbin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib85","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/infdis\/174.6.1176","article-title":"Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys","volume":"174","author":"Putnak","year":"1996","journal-title":"J Infect Dis"},{"key":"10.4103\/0255-0857.148369_bib86","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1016\/j.vaccine.2005.03.042","article-title":"An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model","volume":"23","author":"Robert Putnak","year":"2005","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib87","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.virol.2009.10.023","article-title":"Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy","volume":"396","author":"Simmons","year":"2010","journal-title":"Virology"},{"key":"10.4103\/0255-0857.148369_bib88","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00032-3","article-title":"Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice","volume":"18","author":"Kelly","year":"2000","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib89","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.vaccine.2010.01.022","article-title":"Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys","volume":"28","author":"Clements","year":"2010","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib90","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib91","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4269\/ajtmh.2003.69.129","article-title":"Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris","volume":"69","author":"Guzman","year":"2003","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib92","doi-asserted-by":"crossref","first-page":"e23319","DOI":"10.1371\/journal.pone.0023319","article-title":"A novel single-dose dengue subunit vaccine induces memory immune responses","volume":"6","author":"Chiang","year":"2011","journal-title":"PLoS One"},{"key":"10.4103\/0255-0857.148369_bib93","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0264-410X(97)00215-6","article-title":"Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice","volume":"15","author":"Kochel","year":"1997","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib94","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/S0264-410X(99)00570-8","article-title":"Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein","volume":"18","author":"Raviprakash","year":"2000","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib95","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.virol.2006.05.005","article-title":"A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques","volume":"353","author":"Raviprakash","year":"2006","journal-title":"Virology"},{"key":"10.4103\/0255-0857.148369_bib96","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.vaccine.2005.07.100","article-title":"Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen","volume":"24","author":"Apt","year":"2006","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib97","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s007050050348","article-title":"Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses","volume":"143","author":"Porter","year":"1998","journal-title":"Arch Virol"},{"key":"10.4103\/0255-0857.148369_bib98","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molimm.2012.11.007","article-title":"Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM\/E and NS1: Their immunity and protective efficacy in mice","volume":"54","author":"Lu","year":"2013","journal-title":"Mol Immunol"},{"key":"10.4103\/0255-0857.148369_bib99","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.vaccine.2011.07.019","article-title":"Development of dengue DNA vaccines","volume":"29","author":"Danko","year":"2011","journal-title":"Vaccine"},{"key":"10.4103\/0255-0857.148369_bib100","doi-asserted-by":"crossref","first-page":"6927","DOI":"10.1128\/JVI.02724-07","article-title":"A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus","volume":"82","author":"Raviprakash","year":"2008","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib101","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1128\/JVI.00512-07","article-title":"An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice","volume":"81","author":"White","year":"2007","journal-title":"J Virol"},{"key":"10.4103\/0255-0857.148369_bib102","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1371\/journal.pntd.0000096","article-title":"Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus","volume":"1","author":"Brandler","year":"2007","journal-title":"PLoS Negl Trop Dis"},{"key":"10.4103\/0255-0857.148369_bib103","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1128\/CVI.00330-06","article-title":"Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes","volume":"14","author":"Holman","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.4103\/0255-0857.148369_bib104","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4269\/ajtmh.2007.76.743","article-title":"Induction of bivalent immune responses by expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral vector","volume":"76","author":"Raja","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.4103\/0255-0857.148369_bib105","unstructured":"National Vector Borne Disease Control Programme, Directorate General of Health Services, Ministry of Health and Family Welfare, India, 2013. Dengue cases and deaths in the country since 2007 Available from: http:\/\/nvbdcp.gov.in\/den-cd.html. [Last accessed on 2013 Dec 20]."},{"key":"10.4103\/0255-0857.148369_bib106","unstructured":"Ministry of Health and Family Welfare, Government of India, 2011. Annual report to the people on health. Available from: http:\/\/mohfw.nic.in\/WriteReadData\/l892s\/6960144509Annual%20Report%20to%20the%20People%20on%20Health.pdf [Last accessed on 2013 Dec 20]."},{"key":"10.4103\/0255-0857.148369_bib107","doi-asserted-by":"crossref","first-page":"e7127","DOI":"10.1371\/journal.pntd.0002127","article-title":"Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders","volume":"7","author":"Douglas","year":"2013","journal-title":"Plos Negl Trop Dis"},{"key":"10.4103\/0255-0857.148369_bib108","doi-asserted-by":"crossref","first-page":"e64595","DOI":"10.1371\/journal.pone.0064595","article-title":"Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies","volume":"8","author":"Mani","year":"2013","journal-title":"Plos One"},{"key":"10.4103\/0255-0857.148369_bib109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.342.6157.415","article-title":"Surprising new dengue virus throws a spanner in disease control efforts","volume":"342","author":"Normille","year":"2013","journal-title":"Science"},{"key":"10.4103\/0255-0857.148369_bib110","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1086\/518148","article-title":"Dengue vaccines approach the finish line","volume":"45","author":"Edelman","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721003042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085721003042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T13:23:16Z","timestamp":1621516996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085721003042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0255085721003042"],"URL":"https:\/\/doi.org\/10.4103\/0255-0857.148369","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]}}}